Vaso-Occlusive Crisis clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
open to eligible people ages 12 years and up
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
at UC Irvine UCSF
Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sorry, in progress, not accepting new patients
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
at UC Irvine UCSF
Last updated: